Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Naresh Bumma, MD
Advertisement
Articles by Naresh Bumma, MD
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Single-Tablet Bictegravir/Lenacapavir Effective After Treatment Switch
2
Chemoradiotherapy Improved Survival in Older Patients With Stage 2 NSCLC
3
Noninvasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial
4
Flow Cytometry Tracks CAR T-Cell Therapy Persistence in Aggressive LBCL
5
